Travere Therapeutics, Inc.
Clinical trials sponsored by Travere Therapeutics, Inc., explained in plain language.
-
New drug trial aims to protect transplanted kidneys from damage
Disease control Recruiting nowThis study is testing whether a medication called sparsentan can safely reduce protein in the urine of kidney transplant patients whose original kidney disease has returned. About 20 adult participants who received a transplant at least one year ago will take the daily tablet for…
Phase: PHASE4 • Sponsor: Travere Therapeutics, Inc. • Aim: Disease control
Last updated Apr 02, 2026 00:56 UTC
-
New hope for kids with rare kidney diseases in 2-Year drug trial
Disease control Recruiting nowThis study is testing an oral medication called sparsentan in children aged 1 to 18 with specific rare kidney diseases. The main goal is to see if the drug is safe and can reduce harmful protein loss in urine over 108 weeks. Researchers will enroll about 67 children to monitor th…
Phase: PHASE2 • Sponsor: Travere Therapeutics, Inc. • Aim: Disease control
Last updated Mar 18, 2026 14:40 UTC